1-h Postprandial glucose level is related to the serum anti-Müllerian hormone level in women with polycystic ovary syndrome

References

• Kuzbari O, Doralis J, Peterson CM. Endocrine disorders. In: Berek JS, eds. Berek & Novak’s gynecology. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2012:1075–80
   Google Scholar
• Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004;82:661–5
   PubMed Web of Science ®Google Scholar
• Lin JF, Li X, Zhu MW. Exploration of the classification of polycystic ovarian syndrome. Zhonghua Fu Chan Ke Za Zhi 2006;41:684–8
   PubMedGoogle Scholar
• Chae SJ, Kim JJ, Choi YM, et al. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. Hum Reprod 2008;23:1924–31
   PubMed Web of Science ®Google Scholar
• Fritz MA, Speroff L, eds. Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2011:501–18
   Google Scholar
• Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223–36
   PubMed Web of Science ®Google Scholar
• Legro RS, Arslanian SA, Ehrmann DA, et al. Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4565–92
   PubMed Web of Science ®Google Scholar
• van Rooij IA, Broekmans FJ, Scheffer GJ, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 2005;83:979–87
   PubMed Web of Science ®Google Scholar
• Pigny P, Merlen E, Robert Y, et al. Elevated serum level of antimullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003;88:5957–62
   PubMed Web of Science ®Google Scholar
• Chun S. Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome. Clin Exp Reprod Med 2014;41:86–91
   PubMedGoogle Scholar
• Laven JS, Mulders AG, Visser JA, et al. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004;89:318–23
   PubMed Web of Science ®Google Scholar
• La Marca A, Orvieto R, Giulini S, et al. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 2004;82:970–2
   PubMed Web of Science ®Google Scholar
• Dewaily D, Gronier H, Poncelet E, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011;26:3123–9
   PubMed Web of Science ®Google Scholar
• Eilertsen TB, Vanky E, Carlsen SM. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? Hum Reprod 2012;27:2494–502
   PubMed Web of Science ®Google Scholar
• Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab 2013;98:3332–40
   PubMed Web of Science ®Google Scholar
• de Kat AC, Broekmans FJ, Laven JS, van der Schouw YT. Anti-Müllerian hormone as a marker of ovarian reserve in relation to cardio-metabolic health: a narrative review. Maturitas 2015;80:251--7
   PubMed Web of Science ®Google Scholar
• Nardo LG, Yates AP, Roberts SA, et al. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod 2009;11:2917–23
   Web of Science ®Google Scholar
• Chen MJ, Yang WS, Chen CL, et al. The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod 2008;4:952–7
   Web of Science ®Google Scholar
• Caglar GS, Kahyaoglu I, Pabuccu R, et al. Anti-Mullerian hormone and insulin resistance in classic phenotype lean PCOS. Arch Gynecol Obstet 2013;4:905–10
   Web of Science ®Google Scholar
• Tian X, Ruan X, Mueck AO, et al. Serum anti-Mullerian hormone and insulin resistance in the main phenotypes of non-obese polycystic ovarian syndrome women in China. Gynecol Endocrinol 2014;30:836–9
   PubMed Web of Science ®Google Scholar
• Cassar S, Teede HJ, Moran LJ, et al. Polycystic ovary syndrome and anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins. Clin Endocrinol (Oxf) 2014;81:899–906
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25
   Web of Science ®Google Scholar
• Skalba P, Cygal A, Madej P, et al. Is the plasma anti-Mullerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol 2011;2:254–9
   Web of Science ®Google Scholar
• Lin YH, Chiu WC, Wu CH, et al. Anti-Müllerian hormone and polycystic ovary syndrome. Fertil Steril 2011;96:230–5
   PubMed Web of Science ®Google Scholar
• You SY, Park SY, Yang GY, et al. Anti-Müllerian hormone in women with polycystic ovary syndrome. Korean J Obstet Gynecol 2012;55:315–24
   Google Scholar
• American Diabetes Association. Postprandial blood glucose. American Diabetes Association. Diabetes Care 2001;24:775–8
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M. What is the best predictor of future type 2 diabetes? Diabetes Care 2007;30:1544–8
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Abdul-Ghani T, Ali N, Defronzo RA. One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care 2008;31:1650–5
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Lyssenko V, Tuomi T, et al. Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study. Diabetes Care 2009;32:281–6
   PubMed Web of Science ®Google Scholar